First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873

Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 867

PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624

The Use of Alectinib in the First-Line Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Gadgeel, S. M. (2018) · Future Oncology · doi:10.2217/fon-2018-0027 · Cited by 6

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

Sakamoto, H., Yanagitani, N., Manabe, R., Tsugitomi, R., Ogusu, S., Tozuka, T., Yoshida, H., Amino, Y., Ariyasu, R., Uchibori, K., et al. (2021) · Cancer Reports · doi:10.1002/cnr2.1414 · Cited by 6

Microwave-Induced Improved Synthesis and Antibacterial Activities of Some Chalcones and their 1-Acyl-3,5-Diaryl-2-Piyazolines

Rao, S. S., Gahlot, U. S., Dulawat, S. S., Vyas, R., Ameta, K. L., & Verma, B. L. (2003) · Afinidad · Cited by 6

Resected stage I anaplastic lymphoma kinase‐positive lung adenocarcinoma has a negative impact on recurrence‐free survival

Fujibayashi, Y., Tane, S., Kitazume, M., Kuroda, S., Kimura, K., Kitamura, Y., & Nishio, W. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14365 · Cited by 6

Indirect comparisons of brigatinib and alectinib for front-line ALK -positive non-small-cell lung cancer

Reckamp, K. L., Lin, H. M., Cranmer, H., Wu, Y., Zhang, P., Walton, L., Kay, S., Cichewicz, A. B., Neupane, B., Fahrbach, K. R., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0194 · Cited by 6

A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Chayab, L., Konstantelos, N., Leighl, N. B., Tadrous, M., & Wong, W. W. L. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01279-2 · Cited by 6

Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia

Ngo, P., Karikios, D. J., Goldsbury, D. E., Wade, S. L., Lwin, Z., Hughes, B. G. M., Fong, K. M., Canfell, K., & Weber, M. F. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01291-6 · Cited by 6

Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer

Shih, J., Luo, Y., Chang, G., Chang, J. W., Wang, C.-C., Yang, T., Fang, W., & Shau, W. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.12.019 · Cited by 6

Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC

Gemelli, M. T., Albini, A., Catalano, G., Incarbone, M., Cannone, M., Balladore, E., Ricotta, R., & Pelosi, G. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344648 · Cited by 6

Future Genetic/Genomic Biomarker Testing in Non–Small Cell Lung Cancer

Planchard, D., Remón, J., Nowak, F., & Soria, J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_100007 · Cited by 6

Alectinib for advancedALK-positive non-small-cell lung cancer

Ly, A. C., Olin, J. L., & Smith, M. B. (2018) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp170266 · Cited by 7

The Brigatinib Experience: A New Generation of Therapy for ALK-Positive Non-Small-Cell Lung Cancer

Amanam, I. U., Gupta, R., Mambetsariev, I., & Salgia, R. (2018) · Future Oncology · doi:10.2217/fon-2017-0545 · Cited by 6

Pattern of care and survival of anaplastic lymphoma kinase rearranged non–small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis

Itchins, M., Hayes, S. A., Gill, A. J., Cooper, W. A., O’Connell, R. L., Howell, V. M., Clarke, S. J., & Pavlakis, N. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12877 · Cited by 6

IHC, FISH, CISH, NGS dans les cancers bronchiques non à petites cellules : quelles évolutions dans l’ère des biomarqueurs ?

Hamard, C., Mignard, X., Pécuchet, N., Mathiot, N., Blons, H., Laurent‐Puig, P., Leroy, K., Mansuet‐Lupo, A., Chapron, J., Giraud, F., et al. (2018) · Revue de Pneumologie Clinique · doi:10.1016/j.pneumo.2018.09.013 · Cited by 6

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer

Song, P., Zhang, X., Yang, D., Wang, H., Si, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13376 · Cited by 6

ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases

Aldea, M. D., Besse, B., & Hendriks, L. E. L. (2020) · European Oncology & Haematology · doi:10.17925/eoh.2020.16.1.18 · Cited by 6

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy

Zhai, X., Wu, Q., Pu, D., Yin, L., Wang, W., Zhu, D., & Xu, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.782682 · Cited by 6

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

Martinez‐García, M., Servitja, S., Quintela, N. V., Fernández, A. A., Jaime, A. B., de Ibargüen, B. C. S., Barco, S. D., Campelo, R. G., Sarrió, R. G., & Sepúlveda-Sánchez, J. M. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02803-0 · Cited by 6

Treatment Sequencing Strategies in Lung Cancer.

Pozza, D. H., & de Mello, R. A. (2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.104.01 · Cited by 7

Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients

Grenda, A., Jarosz, B., Krawczyk, P. A., Kucharczyk, T., Wojas‐Krawczyk, K., Reszka, K., Krukowska, K., Nicoś, M., Pankowski, J., Bryl, M., et al. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.28 · Cited by 6

Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study

Huang, Y., Chow, K. K. H., Aredo, J. V., Padda, S. K., Han, S. S., Kakusa, B. W., & Gephart, M. H. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.01.112 · Cited by 6

First-line management of metastatic non-small cell lung cancer: An Indian perspective

Ghadyalpatil, N. S., Pandey, A., Krishnamani, I., Srinivas, C., Rafiq, S. J., Hingmire, S., Maturu, V. N., Reddy, R., Kumar, K., Sreekanth, K., et al. (2019) · South Asian Journal of Cancer · doi:10.4103/sajc.sajc_294_18 · Cited by 6

Systemic Therapy for Mutation-Driven NSCLC

Sun, L., Marmarelis, M. E., & Langer, C. J. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.11.011 · Cited by 6

Blind Identification Of Non-Minimum Phase Systems Using The Mean Differential Cepstrum

Amont, J., Danière, J., & Guilleî, F. (2015) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.37458 · Cited by 6

Lung cancer in India: The rewards of REWERDS (REal World Evidence from Retrospective Data analysiS)

Singh, N. (2020) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2020.100591 · Cited by 6

Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy

Grubb, W., Machtay, M. X., Dowlati, A., & Biswas, T. (2019) · Practical Radiation Oncology · doi:10.1016/j.prro.2018.11.002 · Cited by 5

Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib

Song, G., Li, Y., Kong, W., & Hu, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235679 · Cited by 5

Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation

Chung, C., & Umoru, G. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241242684 · Cited by 5

AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts

Utsumi, T., Mizuta, H., Seto, Y., Uchibori, K., Nishio, M., Okamoto, I., & Katayama, R. (2025) · Cancer Science · doi:10.1111/cas.70006 · Cited by 7

Advances of dual inhibitors based on ALK for the treatment of cancer

Chen, J., Guo, S., He, B., Zheng, W., Jiang, W., Yuan, Z., Xiang, Y., Peng, C., Wei, X., & Shi, J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108417 · Cited by 5

Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials

Kyriacou, N. M., Gross, A. S., & McLachlan, A. J. (2025) · Clinical and Translational Science · doi:10.1111/cts.70224 · Cited by 5

Clinically-meaningful improvements in therapy for unresectable NSCLC

Katakura, S., & Murakami, S. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2102483 · Cited by 5

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort

Zou, Z., Gu, Y., Liang, L., Hao, X., Fan, C., Xin, T., Zhao, S., Liu, Z., Guo, Y., Ma, K., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-803 · Cited by 5

Features of anaplastic lymphoma kinase rearrangement in early‐stage lung cancer: Analysis of a nationwide Japanese database

Matsuura, Y., Mun, M., Shintani, Y., Okami, J., Ito, H., Ohtsuka, T., Mori, T., WATANABE, S.-I. I., Chida, M., Endo, S., et al. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27384 · Cited by 5

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib

Thomas, D. B., Maloney, M. E., & Raval, G. G. (2023) · Cureus · doi:10.7759/cureus.48122 · Cited by 5

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion

Gridelli, C., Tiseo, M., Cortinovis, D. L., Migliorino, M. R., Barbieri, V., Bironzo, P., Bearz, A., Attili, I., & de Marinis, F. (2023) · Current Oncology · doi:10.3390/curroncol30110729 · Cited by 5

Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research

Nicolini, A., Ferrari, P., Silvestri, R., & Bini, D. A. (2025) · MedComm · doi:10.1002/mco2.70373 · Cited by 5

Ascending role of next-generation ALK inhibitors

Costa, D. B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30338-8 · Cited by 5

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

Liao, B.-C., Lin, C., & Yang, J. C. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472765 · Cited by 5

Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung

Balzer, B. W. R., Loo, C. K. C., Wegner, E. A., Nath, C. E., Lee, S., Smith, C., Lewis, C. R., Trahair, T. N., & Anazodo, A. C. (2018) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2018.1541492 · Cited by 5

ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase–positive non-small cell lung Cancer: A clinical perspective

Otoukesh, S., Sanchez, T., Mirshahidi, S., Wallace, D., & Mirshahidi, H. (2019) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2019.100149 · Cited by 5

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Mogenet, A., Tomasini, P., Greillier, L., & Barlési, F. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.05.10 · Cited by 5

Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

Gobbini, É., Chiari, R., Pizzutilo, P., Bordi, P., Ghilardi, L., Pilotto, S., Osman, G. A., Cappuzzo, F., Cecere, F. L., Riccardi, F., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02222-8 · Cited by 5

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control

Huang, S., Huang, A. C., Wang, C., Chang, W., Liu, C., Pavlidis, S. P., Ko, H., Chung, F., Hsu, P., Guo, Y., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13221 · Cited by 5

[Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer].

Song, P., Zhang, L., & Shang, C. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.09.10 · Cited by 5

Patient-Centered Approach to Benefit–Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non–Small-Cell Lung Cancer

Raju, G. K. P., Khozin, S., Gurumurthi, K., Domike, R., & Woodcock, J. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00103 · Cited by 5

Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy

Bronte, G., Cafaro, A., Pasini, L., Priano, I., Andrikou, K., Cravero, P., Burgio, M. A., Delmonte, A., & Crinò, L. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1923485 · Cited by 5

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

Zhang, H., Shan, G., Cai, B., Bi, G., Chen, Z., Liang, J., Besskaya, V., Zheng, Y., Guo, W., Wang, L., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14170 · Cited by 5

Global Research Trends in Tyrosine Kinase Inhibitors: Coword and Visualization Study

Hu, J., Xing, K., Zhang, Y., Liu, M., & Wang, Z. (2022) · JMIR Medical Informatics · doi:10.2196/34548 · Cited by 5

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario

Singh, A. K., Kapoor, A., Noronha, V., Patil, V., Menon, N. S., Mahajan, A., Janu, A., Parandare, N., Kaushal, R., & Prabhash, K. (2022) · ecancermedicalscience · doi:10.3332/ecancer.2022.1407 · Cited by 5

[Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer in the Elderly (2022 Edition)].

(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.101.25 · Cited by 5

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report

Zhao, J., Li, X., Fan, R., Qin, Y., Wang, Z., Wang, B., Li, S., Fan, J., Wu, X., Liu, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1060460 · Cited by 5

Inhibition of the epigenetically activated miR-483-5p/IGF-2 pathway results in rapid loss of meningioma tumor cell viability

Uhlmann, E. J., Mackel, C. E., Deforzh, E., Rabinovsky, R., Brastianos, P. K., Varma, H., Vega, R. A., & Krichevsky, A. M. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04264-z · Cited by 5

An updated patent review of anaplastic lymphoma kinase inhibitors (2018–2022)

Ma, D., Guo, M., & Zhai, X. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2216381 · Cited by 5

Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer

Vavalà, T., Mariniello, A., & Novello, S. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.23 · Cited by 5

Polymeric Micelles in Management of Lung Cancer

Bahman, F., Elkaissi, S., Greish, K. F., & Taurin, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815720-6.00008-3 · Cited by 5

Neuroblastoma

Nguyen, R., & Dyer, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812005-7.00003-5 · Cited by 5

Long‑term complete response in a patient with postoperative recurrent ALK‑rearranged lung adenocarcinoma treated with crizotinib: A case report

Kosaka, T., Yajima, T., Yamaki, E., Nakazawa, S., Tomizawa, K., Onozato, R., Yamazaki, A., Hirato, J., Yatabe, Y., Shimizu, K., et al. (2019) · Molecular and Clinical Oncology · doi:10.3892/mco.2019.1892 · Cited by 5

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib

Liang, H., Ma, D., Xu, Y., Zhao, J., Chen, M., Liu, X., Zhong, W., Li, J., & Wang, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s213572 · Cited by 5

Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC

Urbán, L., Dóczi, R., Vodicska, B., Kormos, D., Tóth, L., Takács, I., Várkondi, E., Tihanyi, D., Lakatos, D., Dirner, A., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030107 · Cited by 5

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China

Zou, Z., Hao, X., Zhang, C., Li, H., Dong, G., Peng, Y., Ma, K., Guo, Y., Li, S., Zhang, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14232 · Cited by 5

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report

Christofyllakis, K., Monteiro, A. R., Cetin, O., Kos, I. A., Greystoke, A., & Luciani, A. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.04.013 · Cited by 5

Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer

Uemura, T., & Hida, T. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.36 · Cited by 5

Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression

Iannantuono, G. M., Giovagnoli, T., Mastrantoni, L., Gyawali, B., Floudas, C. S., Sganga, S., Giannarelli, D., Filetti, M., Spinazzola, A., Bianco, F. L., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106065 · Cited by 4

Anaplastic lymphoma kinase inhibitor development: enhanced delivery to the central nervous system

Hida, T. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-43 · Cited by 4

Recent nanotechnological aspects and molecular targeting strategies for lung cancer therapy

Mishra, L., Kumari, L., Sharma, Y., Chahar, K., Kumar, M., Patel, P., Gupta, G. D., & Kurmi, B. D. (2024) · Journal of Nanoparticle Research · doi:10.1007/s11051-024-06008-0 · Cited by 4

Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Reale, M. L., Scattolin, D., Vitale, A., Passiglia, F., Grisanti, S., Macerelli, M., Galetta, D., Sini, C., Minuti, G., Citarella, F., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108762 · Cited by 5

Data independent acquisition mass spectrometry (DIA-MS) in cancer studies: a concise review

Kumar, B. S. (2025) · Analytical Methods · doi:10.1039/d5ay01294e · Cited by 4

From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy

Yu, J., Zhu, M., Zhu, Y., & Shu, Q. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004704 · Cited by 4

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations

König, D., & Rothschild, S. I. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.019 · Cited by 4

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

Cho, B. C., Kim, D., Batra, U., Park, K., Kim, S., Yang, C., Voon, P. J., Sriuranpong, V., Babu, K. G., Amin, K., et al. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2021.1571 · Cited by 4

[Consensus on Postoperative Recurrence Prediction of Non-small Cell Lung Cancer Based on Molecular Markers].

(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.102.44 · Cited by 4

Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 5

Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non–Small Cell Lung Cancer at a Large Academic Institution in Los Angeles

Poei, D., Ali, S., Thomas, J. S., Nieva, J. J., & Hsu, R. C. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0504 · Cited by 4

Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis

Onesti, C. E., Iacono, D., Angelini, S., Mazzotta, M., Giusti, R., Lauro, S. D., & Marchetti, P. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000699 · Cited by 4

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

Leone, G., Passiglia, F., Bironzo, P., Bertaglia, V., & Novello, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-710 · Cited by 4

Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer

O’Leary, C. G., McSorley, L. M., Hennessy, B. T., Grogan, L., Breathnach, O. S., & Morris, P. G. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801639 · Cited by 4

Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city

Andreev, D. A., Zav’yalov, A. A., Polyakova, K. I., & Davydovskaуa, M. V. (2020) · PULMONOLOGIYA · doi:10.18093/0869-0189-2020-30-4-463-472 · Cited by 4

Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients

Marín, E., Reyes, R., Arcocha, A., Viñolas, N., Mezquita, L., Gonzalvo, E., de Gordoa, K. S., Jares, P., Reguart, N., & Teixidó, C. (2020) · Diagnostics · doi:10.3390/diagnostics10110902 · Cited by 4

Personalized Medicine in Oncology

Vanderwalde, A. M. (2022) · MDPI eBooks · doi:10.3390/books978-3-0365-2820-5 · Cited by 4

Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis

Tan, A. C., Tan, S. H., Zhou, S., Peters, S., Curigliano, G., & Tan, D. S. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102354 · Cited by 4

Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)

Zhou, W., Yan, L.-D., Yu, Z.-Q., Li, N., Yang, Y., Wang, M., Chen, Y., Mao, M.-X., Peng, X., & Cai, J. (2022) · Oncology Letters · doi:10.3892/ol.2022.13301 · Cited by 4

Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China

Su, C., Zhou, J., Qiang, H., Zhao, J., Chang, Q., Ji, X., Li, J., Xie, M., & Chu, T. (2022) · International Journal of Cancer · doi:10.1002/ijc.34123 · Cited by 4

Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma

Liao, J., Guan, H., Yu, M., Zhou, P., Han, Y., Peng, X., & Zhang, S. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01270-2 · Cited by 4

Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India

Gupta, D., Gupta, N. M., Singh, N., & Prinja, S. (2024) · JCO Global Oncology · doi:10.1200/go.23.00260 · Cited by 4

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience

Carlo, E. D., Savio, M. C. D., Polesel, J., Ros, V. D., Berto, E., Santarossa, S., Chimienti, E., Fratino, L., & Bearz, A. (2018) · Oncotarget · doi:10.18632/oncotarget.24573 · Cited by 4

Les avancées dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le réanimateur

Pinsolle, J., Terzi, N., Ferrer, L., Levra, M. G., Toffart, A., & Moro‐Sibilot, D. (2019) · Médecine Intensive Réanimation · doi:10.3166/rea-2019-0091 · Cited by 4

Meta-Analysis Comparing Incidence Of Grade 3 –4 Neutropenia with Alk Inhibitors And Chemotherapy in Patients with Non-Small-Cell Lung Cancer

Rapoport, B. L., Arani, R. B., Mathieson, N., & Krendyukov, A. (2019) · Future Oncology · doi:10.2217/fon-2018-0863 · Cited by 4

Targeted Therapy for Non-Small Cell Lung Cancer

Kim, J. S., & Kang, E. J. (2020) · Korean Journal of Medicine · doi:10.3904/kjm.2020.95.2.78 · Cited by 4

ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases

Tsakonas, G., Kamali, C., Petris, L. D., Friesland, S., Lewensohn, R., & Ekman, S. (2020) · Cancers · doi:10.3390/cancers12071804 · Cited by 4

A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK

Liu, L., Hou, F., Liu, Y., Li, W., & Zhang, H. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7077 · Cited by 4

Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as “ROS1” as it appears?

Singh, N. (2017) · Lung India · doi:10.4103/lungindia.lungindia_305_17 · Cited by 4

Alectinib treatment response in lung adenocarcinoma patient with novel EML4‐ALK variant

Song, P., Zhang, J., Shang, C., & Zhang, L. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12834 · Cited by 4

Stratégies thérapeutiques dans le cancer bronchique non à petites cellules ALK positif de stade IV

Tiotiu, A. I., Billon, Y., Vaillant, P., Ménard, O., Hofman, P. M., & Mascaux, C. (2019) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2019.02.008 · Cited by 4

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status

Taketa, T., & Nakamura, T. (2021) · Clinical Case Reports · doi:10.1002/ccr3.3927 · Cited by 4

Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe

Lasala, R., Santoleri, F., Romagnoli, A., Musicco, F., & Costantini, A. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-02621-w · Cited by 4

An Ascendant Challenge: Central Nervous System Metastases in ALK + Lung Cancers

Murciano-Goroff, Y. R., Harada, G., & Drilon, A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0341 · Cited by 4

Immunotherapeutic and Targeted Strategies for Managing Brain Metastases from Common Cancer Origins: A State-of-the-Art Review

Podder, V., Bellur, S. S., Margolin, K. A., Advani, P. P., Mahtani, R. L., Subbiah, V., Novo, G. B., Ranjan, T., & Ahluwalia, M. S. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01593-8 · Cited by 4

SDMap: a comprehensive database of spatial drug perturbation maps

Li, F., Chen, Z., Zhang, Y., Ye, X., Fan, W., 康安辉, Song, X., Pei, L., Quan, Q., Liu, W., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1046 · Cited by 3

Crizotinib- or Ceritinib-Conjugated Platinum(IV) Prodrugs As Potent Multiaction Agents Inducing Antiproliferative Effects in 2D and 3D Cancer Cell Models

Sharkawy, S., Acharya, S., Kostrhunová, H., Maji, M., Marková, L., Novohradský, V., Gibson, D., & Brabec, V. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01858 · Cited by 3

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)

de Castro, G., Tan, D. S.-W., Crinò, L., Wu, Y.-L. L. C., Paz-Ares, L. G., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D. L., Yu, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.008 · Cited by 12

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O. P., Mok, T. S. K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30339-x · Cited by 576

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

Tan, D. S. W., Geater, S. L., Yu, C., Tsai, C., Hsia, T., Chen, J., Lin, M., Lü, Y., Sriuranpong, V., Yang, C., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100131 · Cited by 11

First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis

Tan, D. S. W., Geater, S. L., Yu, C., Tsai, C., Hsia, T., Zhou, J., Chen, J., Lin, M. C., Yu, P., He, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz259.016 · Cited by 3

Ceritinib is superior to frontline chemotherapy

Sidaway, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.20 · Cited by 1